Researchers from the University of Osaka and Chulalongkorn University have developed a new drug delivery system that could improve the effectiveness of cannabidiol (CBD) against colorectal cancer.
The team created pH-responsive microparticles made from polyhydroxybutyrate (PHB) and cellulose acetate phthalate (CAP), both biocompatible polymers that protect CBD as it moves through the digestive tract. They demonstrated their finding in a study published by the International Journal of Biological Macromolecules.
Using response surface methodology, they optimized the formulation to achieve high encapsulation efficiency (71.8%) and stability, with the microparticles maintaining over 80% of CBD content after 90 days of storage at 4 °C. The particles averaged 211 micrometers in size and were designed to release CBD over a six-hour period in response to intestinal pH.
In lab tests, the CBD microparticles significantly inhibited the growth of Caco-2 colorectal cancer cells in a dose-dependent manner, with IC50 values of 129 μg/mL at 24 hours and 144 μg/mL at 48 hours. These results indicate promising anticancer activity while also addressing CBD’s known limitations, including poor solubility, instability in acidic environments, and low bioavailability.
The researchers concluded that PHB/CAP-based pH-responsive microparticles could provide a stable, controlled-release platform for delivering CBD as an anticancer therapy. Their work highlights the potential for more targeted and less toxic treatment options for colorectal cancer patients compared with conventional chemotherapy.
Sponsored
